Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Related Citations for PubMed (Select 22829267)

1.

A randomized trial of mesenchymal stem cells in multiple system atrophy.

Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS, Cheong JW, Jeong Y, Park HJ, Kim DJ, Nam CM, Lee JD, Kim HO, Sohn YH.

Ann Neurol. 2012 Jul;72(1):32-40. doi: 10.1002/ana.23612.

PMID:
22829267
2.

Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy.

Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K.

Clin Pharmacol Ther. 2008 May;83(5):723-30. Epub 2007 Sep 26.

PMID:
17898702
3.

Mesenchymal stem cells can modulate longitudinal changes in cortical thickness and its related cognitive decline in patients with multiple system atrophy.

Sunwoo MK, Yun HJ, Song SK, Ham JH, Hong JY, Lee JE, Lee HS, Sohn YH, Lee JM, Lee PH.

Front Aging Neurosci. 2014 Jun 13;6:118. doi: 10.3389/fnagi.2014.00118. eCollection 2014.

4.

Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).

Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, Frick C, Ndayisaba JP, Ulmer H, Pellecchia MT, Barone P, Kim HT, Hooker J, Quinn NP, Cardozo A, Tolosa E, Abele M, Klockgether T, Østergaard K, Dupont E, Schimke N, Eggert KM, Oertel W, Djaldetti R, Poewe W; European MSA Study Group.

Mov Disord. 2006 Feb;21(2):179-86.

PMID:
16161136
5.

Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy.

Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, Rinne JO, Lee MS.

Brain. 2008 Feb;131(Pt 2):438-46. doi: 10.1093/brain/awm328. Epub 2008 Jan 4.

6.

Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism.

Park HJ, Bang G, Lee BR, Kim HO, Lee PH.

Cell Transplant. 2011;20(6):827-35. doi: 10.3727/096368910X540630. Epub 2010 Nov 5.

PMID:
21054946
7.

The European Multiple System Atrophy-Study Group (EMSA-SG).

Geser F, Seppi K, Stampfer-Kountchev M, Köllensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK; EMSA-SG.

J Neural Transm. 2005 Dec;112(12):1677-86. Epub 2005 Jul 29. Review.

PMID:
16049636
8.

Cerebral atrophy in multiple system atrophy by MRI.

Horimoto Y, Aiba I, Yasuda T, Ohkawa Y, Katayama T, Yokokawa Y, Goto A, Ito Y.

J Neurol Sci. 2000 Feb 15;173(2):109-12.

PMID:
10675653
9.

Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial).

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K.

Mov Disord. 2010 Jan 15;25(1):97-107. doi: 10.1002/mds.22732.

PMID:
20014118
10.

Potential outcome measures and trial design issues for multiple system atrophy.

May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW; North American Multiple System Atrophy Study Group.

Mov Disord. 2007 Dec;22(16):2371-7.

PMID:
17914727
11.

Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration.

Chang CC, Chang YY, Chang WN, Lee YC, Wang YL, Lui CC, Huang CW, Liu WL.

Eur J Neurol. 2009 Oct;16(10):1144-50. doi: 10.1111/j.1468-1331.2009.02661.x. Epub 2009 May 22.

PMID:
19486137
12.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
13.

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J, Dupont WD, Chelimsky T, Galpern WR.

Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6. Epub 2014 Feb 5.

14.

Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis.

Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, Bashtar M, Ghavamzadeh A, Malekzadeh R.

Liver Int. 2013 Nov;33(10):1490-6. doi: 10.1111/liv.12228. Epub 2013 Jun 14.

PMID:
23763455
15.

The natural history of multiple system atrophy: a prospective European cohort study.

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Köllensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, del Sorbo F, Tolosa E, Cardozo A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner WG, Tison F, Poewe W; European Multiple System Atrophy Study Group.

Lancet Neurol. 2013 Mar;12(3):264-74. doi: 10.1016/S1474-4422(12)70327-7. Epub 2013 Feb 5.

16.

Quantifying cerebellar atrophy in multiple system atrophy of the cerebellar type (MSA-C) using three-dimensional gyrification index analysis.

Wu YT, Shyu KK, Jao CW, Liao YL, Wang TY, Wu HM, Wang PS, Soong BW.

Neuroimage. 2012 May 15;61(1):1-9. doi: 10.1016/j.neuroimage.2012.02.057. Epub 2012 Feb 28.

PMID:
22401757
17.

Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time.

Damon-Perrière N, Foubert-Samier A, De Cock VC, Gerdelat-Mas A, Debs R, Pavy-Le Traon A, Senard JM, Rascol O, Tison F, Meissner WG.

Parkinsonism Relat Disord. 2012 Jun;18(5):612-5. doi: 10.1016/j.parkreldis.2011.12.009. Epub 2012 Jan 9.

PMID:
22236582
18.

Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy-a comparison between clinical subtypes and correlations with clinical parameters.

Minnerop M, Specht K, Ruhlmann J, Schimke N, Abele M, Weyer A, Wüllner U, Klockgether T.

Neuroimage. 2007 Jul 15;36(4):1086-95. Epub 2007 Apr 25.

PMID:
17512219
19.

Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells.

Dongmei H, Jing L, Mei X, Ling Z, Hongmin Y, Zhidong W, Li D, Zikuan G, Hengxiang W.

Cytotherapy. 2011 Sep;13(8):913-7. doi: 10.3109/14653249.2011.579958. Epub 2011 May 5.

PMID:
21545234
20.

Autologous mesenchymal stem cell transplantation in stroke patients.

Bang OY, Lee JS, Lee PH, Lee G.

Ann Neurol. 2005 Jun;57(6):874-82.

PMID:
15929052
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk